{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-039013","form_type":"8-K","ticker":"IRWD","cik":"0001446847","company_name":"IRONWOOD PHARMACEUTICALS INC","filed_at":"2025-04-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.320913+00:00","generated_at":"2026-05-23T05:47:50.365911+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Ironwood reiterates FY2025 LINZESS guidance, raises EBITDA to >$105M; Q1 net sales down 46%","bullets":["Reiterates FY2025 LINZESS U.S. net sales guidance of $800-$850M and total revenue of $260-$290M.","Raises FY2025 adjusted EBITDA guidance to >$105M (from >$85M).","Q1 2025 LINZESS U.S. net sales were $138.5M, a 46% decrease YoY due to change in AbbVie's gross-to-net rebate estimate.","Q1 2025 LINZESS prescription demand grew 8% YoY to 53M capsules, per IQVIA.","Shifts apraglutide focus to confirmatory Phase 3 trial after FDA feedback; no longer plans certain commercial launch investments."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-039013","json":"https://secwatch.observer/filing/0001104659-25-039013.json","markdown":"https://secwatch.observer/filing/0001104659-25-039013.md","text":"https://secwatch.observer/filing/0001104659-25-039013.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1446847/000110465925039013/0001104659-25-039013-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1446847/000110465925039013/tm2513134d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T05:47:50.365911+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}